Skip to content

Clinical trials

Immunoblastic Lymphadenopathy trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Immunoblastic Lymphadenopathy Phase: Not applicable Clear all

24 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20021
20041
20061
20074
20081
20092
20101
20111
20131
20151
20161
20201
20231

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed11
Terminated5
Withdrawn5
Unknown status2
Active, not recruiting1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Fred Hutchinson Cancer Center4
Eastern Cooperative Oncology Group2
M.D. Anderson Cancer Center2
Mayo Clinic2
Wake Forest University Health Sciences2
Asan Medical Center1
Astex Pharmaceuticals, Inc.1
Case Comprehensive Cancer Center1
City of Hope Medical Center1
European Organisation for Research and Treatment of Cancer - EORTC1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Immunoblastic Lymphadenopathy24
Lymphoma, Large-Cell, Anaplastic22
Lymphoma, Large B-Cell, Diffuse21
Leukemia, Lymphocytic, Chronic, B-Cell20
Burkitt Lymphoma19
Lymphoma, Follicular19
Lymphoma, Mantle-Cell19
Mycosis Fungoides19
Sezary Syndrome19
Lymphoma, B-Cell, Marginal Zone18

Trials

Showing 76 to 24 of 24. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.